New and Updated - Books

New & Updated

Here is a list of recently added titles to Bookshelf and updated books and releases

Recent Releases

Testing a Health Coaching Program to Help Patients with Obesity Lose Weight—The PROPEL Study [Internet].

Katzmarzyk PT, Martin CK, Newton RL Jr, et al.

Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 Jun.

Added 04-17-2024

Incorporating Integrated Diagnostics into Precision Oncology Care: Proceedings of a Workshop [Prepublication Draft].

National Cancer Policy Forum; Board on Health Care Services; Board on Human-Systems Integration; Computer Science and Telecommunications Board; Division of Behavioral and Social Sciences and Education; Division on Engineering and Physical Sciences; Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine.

Washington (DC): National Academies Press (US); 2024 Apr 17.

Added 04-17-2024

Body Mass Index as a Measure of Obesity and Cut-Off for Surgical Eligibility: Technology Review [Internet].

Khangura SD, Severn M; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Helping Patients with Mental Illness Engage in Their Transitional Care [Internet].

Velligan DI, Fredrick M, Sierra C, et al.

Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2019 Aug.

Added 04-15-2024

Nusinersen (Spinraza): CADTH Reimbursement Review: Therapeutic area: Spinal Muscular Atrophy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.

Added 04-15-2024

Octreotide Long-Acting Release and Everolimus for Recurrent Meningiomas: Rapid Review [Internet].

Jafari Z, Horton J; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Empagliflozin (Jardiance): CADTH Reimbursement Recommendation: Indication: Indicated in adults as an adjunct to standard-of-care therapy for the treatment of chronic heart failure [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Oseltamivir for the Prevention of Influenza in Residents of Long-Term Care Facilities: Rapid Review [Internet].

Subramonian A, Horton J; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Treatment Options for VEXAS Syndrome: Rapid Review [Internet].

Goring S, Horton J; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Peer Support Programs for Youth Mental Health: Health Technology Assessment [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

View More Recent Releases

Pegvaliase (Palynziq): CADTH Reimbursement Recommendation: Indication: For the treatment of patients with phenylketonuria aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) on existing management [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: Adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

ClotChip Portable Blood Clotting Sensor: Health Technology Update [Internet].

Khangura SD, McGill SC; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Transanal Total Mesorectal Excision for Adults With Rectal Cancer: Rapid Review [Internet].

Barbara AM, Subramonian A, Horton J; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Faricimab (Vabysmo): CADTH Reimbursement Review: Therapeutic area: Macular degeneration, age-related [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Entrectinib (Rozlytrek): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation and with no satisfactory treatment options [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Cabozantinib (Cabometyx): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Robotic Surgical Systems for Orthopedics: Emerging Health Technologies [Internet].

Smith A, Picheca L, Mahood Q; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Cariprazine (Vraylar): CADTH Reimbursement Recommendation: Indication: As monotherapy for: bipolar mania: acute management of manic or mixed episodes associated with bipolar I disorder in adults, and bipolar depression: acute management of depressive episodes associated with bipolar I disorder in adults [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Prostate-Specific Membrane Antigen PET-CT Imaging for the Staging of Prostate Cancer in Canada: CMII Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Raltitrexed in Patients With Dihydropyrimidine Dehydrogenase Deficiency: Rapid Review [Internet].

Vu T, Spry C; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Rapid Syphilis Testing: Health Technology Update [Internet].

Clark M, Grobelna A; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Developing Software for Using Bayesian Regression to Evaluate Heterogeneity of Treatment Effects in Data from Randomized Controlled Trials [Internet].

Varadhan R, Louis TA, Wang C, et al.

Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2018 Jul.

Added 04-15-2024

Do Palliative Care Teams in Nursing Homes Improve the Quality of End-of-Life Care for Nursing Home Residents? [Internet].

Temkin-Greener H, Mukamel DB, Ladwig S, et al.

Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2019 Jul.

Added 04-15-2024

Mogamulizumab (Poteligeo): CADTH Reimbursement Review: Therapeutic area: Mycosis fungoides, Sézary syndrome [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Added 04-15-2024

Updated

RSS Feed

RSS Feed for New Releases

Recent Activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on